Търсене на изпитвания

Активни:

Намерени 3,079 изпитвания Стр. 11 от 154

Набира участници Фаза 1

A Study of AZD0120 in Autoimmune Diseases

Systemic Sclerosis Idiopathic Inflammatory Myopathies Rheumatoid Arthritis

This trial is a Phase 1b, open-label, multi-center, clinical study of AZD0120, a BCMA/CD19 dual targeting CAR+ T-cell therapy, to evaluate the safety and tolerability in adult participants with systemic sclerosis (SSc), idiopathic inflammatory myopathies (IIM), or difficult-to-treat rheumatoid arthritis (D2T RA).

Начало: 09.01.2026 Край: 22.02.2028 Възраст: 18–75 г. Лечение

Australia, Germany, Spain +2 AstraZeneca NCT07295847

Набира участници Фаза 1

A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies

Solid Tumors Hematologic Malignancies

A study to evaluate the safety and tolerability of INCA036873 in participants with advanced solid tumors and hematological malignancies.

Начало: 08.01.2026 Край: 18.08.2028 Възраст: от 18 г. Лечение

Australia, Belgium, Denmark +2 Incyte Corporation NCT07195916

Набира участници Фаза 1

A Study to Find a Suitable Dose of Exl-111 for Further Research

Allergic Disease

This is a Phase 1, randomized, double-blind, placebo-controlled, single and multiple ascending dose trial of Exl-111 in healthy participants. The trials consists of 2 parts, as follows: Part A (SAD): Up to 5 dose cohorts, each with 8 participants, randomized into 2 arms: Exl-111 and placebo. Part B (MAD): Up to 3 dose cohorts, each with 10 participants, randomized into 3 arms: Exl-111, placebo, and an active comparator (omalizumab).

Начало: 08.01.2026 Край: 07.12.2026 Възраст: 18–55 г. Лечение

Australia Excellergy Inc. NCT07356713

Набира участници Фаза 3

A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight

Overweight Obesity

This study will look at how well CagriSema and cagrilintide help children and adolescents with excess body weight lose weight. The study has 2 parts: main and extension study. In the main study, participants will either get CagriSema (a new study drug), cagrilintide (a new study drug), semaglutide (a drug that doctors can already prescribe to adolescents and adults) or placebo (a placebo looks like the treatment being tested, but doesn't have any active ingredients in it). Which treatment participants will get is decided by chance. Participants who get semaglutide in the main study will not take part in the extension study. If participants take part in the extension study, they will get either CagriSema or cagrilintide in this part of the study. Like all drugs, the study drugs may have side effects. The total time participants will be in the main study is about 1 year and 6 months. If participants take part in the extension study, the total time is about 4 years and 10 months.

Начало: 08.01.2026 Край: 20.09.2033 Възраст: 8–18 г. Лечение

Australia, Belgium, Bulgaria +21 Novo Nordisk A/S NCT07253285

Набира участници

Sensory Toys for Anxiety Reduction - Can Fidget Toys Improve Stress and Help Children to Cope Before Surgery (STARFISH)

Perioperative Anxiety

Anxiety associated with medical procedures is common, with 40-80% of children experiencing significant symptoms and postoperative consequences, including distress and delirium, increased intensity/duration of pain, prolonged hospital stays, behavioural/sleep disturbance and avoidance of medical encounters, which often remain into adulthood. Extensive consumer research has shown that a key priority for Australian consumers of all ages in relation to paediatric hospital care is addressing the fear and anxiety in children throughout the hospital experience (second only to anaesthesia safety for adults and third following anaesthesia safety and pain management for children). The STARFISH trial was driven by our consumer partners, particularly our youth consumers. It is well known that distraction is a coping strategy that can help with perioperative anxiety, and all members of the perioperative team commonly employ distraction techniques with patients during routine clinical care. One potential form of distraction involves sensory activities - fidget devices or sensory toys such as spinners, putty, and stability balls are increasingly being used within school settings to help students academically and behaviourally, with applicability for neurodiverse (e.g., autistic, Attention Deficit Hyperactivity Disorder (ADHD)) children being one area of particular interest. However, the research behind sensory toys is inconclusive. Sensory toys have been suggested to our team-from numerous consumers of all ages, including neurodiverse and neurotypical consumers-as a method to reduce anxiety in the preoperative period, thus leading to the design of the STARFISH trial. This project aims to assess the use of a sensory toy (of the child's choice) in the perioperative period on the day of surgery to reduce perioperative anxiety and distress.

Начало: 08.01.2026 Край: 30.12.2028 Възраст: 5–15 г. Превенция

Australia, Brazil Telethon Kids Institute NCT07270029

Набира участници Фаза 3

Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

Pulmonary Hypertension Interstitial Lung Disease

The primary objective of this study is to evaluate the effect of 24-weeks of once daily treatment with TPIP versus placebo on exercise capacity in adults with PH-ILD.

Начало: 07.01.2026 Край: 30.12.2028 Възраст: от 18 г. Лечение

Argentina, Australia, Belgium +17 Insmed Incorporated NCT07179380

Набира участници

The Effects of Insomnia Treatment on Overnight Regulation of Emotional Memories and Risk for Mental Disorders

Insomnia Chronic Anxiety

This project aims to elucidate whether CBCTi changes symptom severity or even remission of anxiety disorders as compared with a delayed-start control group. The investigators will use a delayed-start randomized controlled trial in a cohort of individuals with anxiety and insomnia (N=98) to compare the effects of an online therapist-guided cognitive behavioural and circadian therapy for insomnia versus control on overnight emotion regulation and mental health outcomes. The project will involve at-home assessments and in-lab visits. At-home assessment involves recording sleep and circadian rhythm measures with wearables and daily diaries. Participants will be invited to perform two sleep studies and neuroimaging sessions to investigate the effects of CBCTi on neuroimaging and psychophysiological markers of overnight regulation of emotional distress.

Начало: 06.01.2026 Край: 01.06.2030 Възраст: 18–45 г. Лечение

Australia Woolcock Institute of Medical Research NCT06567210

Набира участници Фаза 1

A Study of SYNT-101 to Test Safety, Tolerability and Pharmacodynamics of SYNT-101 in Healthy and Overweight Adults

Healthy Overweight and Obese Adults

A Phase 1, single-center, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and pharmacodynamics of single and multiple dose regimens of SYNT-101 in healthy and overweight adults.

Начало: 05.01.2026 Край: 31.12.2026 Възраст: 18–55 г. Лечение

Australia Syntis Bio NCT07307274

Набира участници Ранна Фаза 1

A Trial of HRS-5817 in Obese Participants

Obesity

The purpose of this study is to assess safety, PK, Pharmacodynamic and immunogenicity profile of a single dose of HRS-5817 in obese participants

Начало: 05.01.2026 Край: 30.01.2027 Възраст: 18–55 г. Лечение

Australia Atridia Pty Ltd. NCT07238647

Набира участници Фаза 2

A Rollover Study Evaluating Sotorasib With or Without Panitumumab in Participants With KRAS p.G12C Mutation

Advanced Solid Tumors

The primary objective of the study is to evaluate the safety and tolerability of the continuation of sotorasib with or without panitumumab and/or other anti-cancer therapies in participants continuing to derive benefit in Amgen-sponsored protocols.

Начало: 02.01.2026 Край: 02.01.2028 Възраст: от 18 г. Лечение

Australia, France, Germany +5 Amgen NCT07172919

Набира участници Фаза 2/3

A Study to Compare the Combination of BMS-986504 With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

Metastatic Non-small Cell Lung Cancer With MTAP Deletion

The purpose of this study is to compare the clinical benefit of the combination of BMS-986504 (a selective MTA-cooperative inhibitor of PRMT5) plus pembrolizumab and chemotherapy versus placebo plus pembrolizumab and chemotherapy in first-line metastatic non-small cell lung cancer participants with homozygous MTAP deletion

Начало: 02.01.2026 Край: 12.08.2031 Възраст: от 18 г. Лечение

Argentina, Australia, Belgium +28 Bristol-Myers Squibb NCT07063745

Набира участници Фаза 2

A Study to Evaluate the Effects of the Combination of GI-102 With GIB-7 on Biomarkers of Aging in Healthy Adults and Cancer Survivors

Cancer Survivors Healthy Participant Elderly

This Phase 2a clinical study (GIANTS-1) aims to evaluate a novel dual-combination strategy using GI-102 and GIB-7 to address key pathological features of aging, including immunosenescence (the aging of the immune system), metabolic dysfunction, and gut-brain-muscle axis dysregulation.

Начало: 01.01.2026 Край: 01.10.2026 Възраст: 18–80 г. Лечение

Australia GI Innovation, Inc. NCT07363057

Набира участници Фаза 2

Plan A Occlusion and Reversal System Feasibility Study

Fertility Fertility, Male Healthy Male Adults

Prospective, multicenter, single-arm, open label, interventional clinical trial investigating the safety and effectiveness of the Plan A Male Contraceptive System to occlude the vas deferens to block the passage of sperm and then be reversed to subsequently allow the passage of sperm through the vas deferens.

Начало: 01.01.2026 Край: 01.09.2026 Възраст: 25–65 г. Лечение

Australia Next Life Sciences NCT07361120

Набира участници Фаза 2/3

A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer

Untreated, Unresectable, or Metastatic Colorectal Cancer

The purpose of this study is to evaluate the safety and efficacy of pumitamig in combination with chemotherapy versus bevacizumab in combination with chemotherapy in participants with previously untreated, unresectable, or metastatic colorectal cancer

Начало: 31.12.2025 Край: 11.03.2034 Възраст: от 18 г. Лечение

Argentina, Australia, Belgium +22 Bristol-Myers Squibb NCT07221357

Набира участници Фаза 1

A Study to Investigate the Safety, Pharmacodynamic and Pharmacokinetic Characteristics of CBP-4888 in Hospitalized Participants With Preterm Preeclampsia and Their Children up to 24 Months

sFlt1 Mediated Preterm Preeclampsia Preeclampsia Preterm Preeclampsia

This study is a dose finding study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of subcutaneous CBP-4888 in hospitalized participants with Preterm Preeclampsia receiving Standard of Care, Expectant Management. Eligible participants are between 26 +0/7 and 35 +6/7 weeks gestational age and clinically appropriate for inpatient expectant management. Eligible participants will receive standard of care expectant management for their pregnancy with the only study interventions being one subcutaneous dose of CBP-4888. Participants will: * receive a single subcutaneous injection dose of CBP-4888 and will be followed through delivery and for 42 days (+14 days) after delivery. Participants will be followed through 6 weeks post delivery. * Infants will be evaluated immediately postpartum and then followed through 24 months of age with standard infant and pediatric assessments with phone calls made to parents.

Начало: 31.12.2025 Край: 31.03.2029 Възраст: 18–45 г. Лечение

Australia Comanche Biopharma NCT07282171

Набира участници Фаза 1

An Early Phase Study of RT-114 (RaniPill Containing PG-102, a GLP-1/2 Dual Agonist) in Healthy Volunteers.

Obesity

The goal of this Phase 1 study is to evaluate the safety and tolerability of RT-114 in healthy volunteers. The main objectives are: Primary: To evaluate safety and tolerability of RT-114 when administered as single and multiple doses by assessing treatment emergent adverse events (TEAEs) in healthy volunteers Secondary: * To determine the pharmacokinetics of RT-114 administered as single and multiple doses * To determine the pharmacodynamic effects of RT-114 administered as multiple doses In the single dose portion of the study participants will either receive the drug via a subcutaneous injection or an oral pill (RT-114). In the repeat dose portion of the study participants will randomized to either RT-114 or a placebo.

Начало: 30.12.2025 Край: 01.06.2027 Възраст: 18–65 г. Лечение

Australia RANI Therapeutics NCT06891287

Набира участници Фаза 1

A Study to Investigate Safety, Tolerability and Pharmacokinetics of LAE103 or LAE103 in Combination With LAE102 in Healthy Overweight/Obese Participants

Overweight and Obesity

The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of LAE103 injection in healthy overweight/obese participants or healthy postmenopausal women. Study will also evaluate the safety, tolerability and preliminary pharmacodynamic effect of multiple dose injections in overweight/obese participants. In addition, the study will also investigate the safety, tolerability of a single-dose co-administration of LAE102 and LAE103 in healthy overweight/obese participants.

Начало: 30.12.2025 Край: 20.03.2028 Възраст: 18–75 г. Фундаментална наука

Australia Laekna Limited NCT07230496

Набира участници Фаза 2

Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders

Immune Thrombocytopenia

This study will evaluate the safety and efficacy of tafasitamab in adult participants with primary autoimmune blood cell disorders.

Начало: 29.12.2025 Край: 09.03.2028 Възраст: от 18 г. Лечение

Australia, France, Italy +4 Incyte Corporation NCT07104565

Набира участници Фаза 3

AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer

Epithelial Ovarian Cancer

The intention of the study is to demonstrate superiority of AZD5335 versus standard of care by assessment of progression-free survival (PFS) in women with high-grade, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, expressing high or low FRα levels.

Начало: 29.12.2025 Край: 27.05.2030 Възраст: от 18 г. Лечение

Australia, Belgium, Brazil +17 AstraZeneca NCT07218809

Набира участници Фаза 3

A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant

Multiple Myeloma

This study is researching an experimental drug called linvoseltamab. The study is focused on participants with newly diagnosed multiple myeloma (NDMM) who are ineligible for autologous stem cell transplantation (transplant-ineligible). The main purpose of this study is to compare the effect and safety of linvoseltamab with the effect and safety of the standard treatment.

Начало: 23.12.2025 Край: 01.12.2036 Възраст: от 18 г. Лечение

Australia, Croatia, Czechia +12 European Myeloma Network B.V. NCT06932562

1 … 9 10 11 12 13 … 154